Arcturus Therapeutics Holdings (ARCT) Cash from Investing Activities (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) posted Cash from Investing Activities of $34000.0 for Q1 2026, down 61.36% on a QoQ basis from $88000.0 in Q4 2025, and up 124.82% year-over-year from $15123.4 in Q1 2025.
Arcturus Therapeutics Holdings (ARCT) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at $34000.0 for Q1 2026.
- Quarterly Cash from Investing Activities rose 124.82% year-over-year to $34000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$59000.0 (up 89.17% YoY) and the FY2025 annual result came in at -$230000.0, up 64.51% from the prior year.
- Cash from Investing Activities was $34000.0 for Q1 2026 at Arcturus Therapeutics Holdings, down from $88000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $378000.0 in Q2 2022 and bottomed at -$3.8 million in Q4 2022.
- A 5-year average of -$764733.3 and a median of -$328000.0 in 2024 frame the typical range for Cash from Investing Activities.
- Peak annual rise in Cash from Investing Activities reached 193.56% in 2022, while the deepest fall reached 1688.98% in 2022.
- Arcturus Therapeutics Holdings' Cash from Investing Activities stood at -$3.8 million in 2022, then soared by 77.02% to -$875000.0 in 2023, then surged by 90.86% to -$80000.0 in 2024, then surged by 210.0% to $88000.0 in 2025, then sank by 61.36% to $34000.0 in 2026.
- Business Quant data shows ARCT's Cash from Investing Activities at $34000.0 in Q1 2026, $88000.0 in Q4 2025, and -$181000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Arcturus Therapeutics Holdings | 164.42 Mn | -46.96 Mn | - | 34,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34,000.00 |
| Mar 31, 2026 | 34,000.00 |
| Dec 31, 2025 | 88,000.00 |
| Dec 31, 2025 | 88,000.00 |
| Sep 30, 2025 | -181,000.00 |
| Sep 30, 2025 | -181,000.00 |
| Mar 31, 2025 | -137,000.00 |
| Mar 31, 2025 | -137,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Jun 30, 2024 | -328,000.00 |
| Jun 30, 2024 | -328,000.00 |
| Mar 31, 2024 | -240,000.00 |
| Mar 31, 2024 | -240,000.00 |
| Dec 31, 2023 | -875,000.00 |
| Dec 31, 2023 | -875,000.00 |
| Sep 30, 2023 | -981,000.00 |
| Sep 30, 2023 | -981,000.00 |
| Jun 30, 2023 | -354,000.00 |
| Jun 30, 2023 | -354,000.00 |